FDA Clearance Tracker · P160007-S047
Simplera System
Last checked: Nov 20, 2026Latest source record: Jul 24, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jul 24, 2024
Approved
Time to decision
525 days
Received Feb 15, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160007-S047
- Device name
- Simplera System
- Applicant
- Medtronic Minimed
- Applicant location
- Northridge, CA
- Received
- Feb 15, 2023
- Decided
- Jul 24, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P160007
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Simplera system. The Simplera system is a real-time continuous glucose monitoring (CGM) system indicated for the management of diabetes in persons ages 18 years and older. The Simplera system does not require calibration and is designed to replace fingerstick blood glucose (BG) testing for diabetes treatment decisions, unless otherwise indicated. Interpretation of the Simplera system results should be based on the glucose trends and several sequential sensor readings over time.
Source documents
Other decisions for Medtronic Minimed
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261962 · Decided Jul 9, 2026 · 28 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.